Mycoplasma pneumoniae infections–does treatment help?
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, neither serological testing nor polymerase chain reaction (PCR) can reliably distinguish active infection from asymptomatic carriage, creating significant challenges for clinicians in determining whether and when to initiate antimicrobial therapy (Spuesens et al., 2014; Meyer Sauteur et al., 2016).”
From Advances in adhesion-related pathogenesis in Mycoplasma pneumoniae infection (2025) · cites this paper as Spuesens et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology and etiology of childhood pneumonia
Rudan, I. (2008) · Bulletin of the World Health Organization · doi:10.2471/blt.07.048769 · Cited by 1,422
Mycoplasma pneumoniae and Its Role as a Human Pathogen
Waites, K. B., & Talkington, D. F. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.4.697-728.2004 · Cited by 1,339
Interaction of Mycoplasmas With Host Cells
Rottem, S. (2003) · Physiological Reviews · doi:10.1152/physrev.00030.2002 · Cited by 432
Research works printed but not linked: 44
- Michelow, 2004, Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children, Pediatrics, 113, 701, 10.1542/peds.113.4.701 · DOI · Paper page
- Himmelreich, 1996, Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae, Nucleic Acids Res, 24, 4420, 10.1093/nar/24.22.4420 · DOI · Paper page
- Ruland, 1994, Sequence divergence in the ORF6 gene of Mycoplasma pneumonia, J Bacteriol, 176, 5202, 10.1128/jb.176.17.5202-5209.1994 · DOI
- Krause, 2001, Structure, function, and assembly of the terminal organelle of Mycoplasma pneumoniae, FEMS Microbiol Lett, 198, 1, 10.1111/j.1574-6968.2001.tb10610.x · DOI
- Rottem, 2000, Mycoplasma interaction with eukaryotic cells, Subcell Biochem, 33, 199, 10.1007/978-1-4757-4580-1_9 · DOI
- Balish, 2003, Deletion analysis identifies key functional domains of the cytadherence-associated protein HMW2 of Mycoplasma pneumoniae, Mol Microbiol, 50, 1507, 10.1046/j.1365-2958.2003.03807.x · doi:10.1046/j.1365-2958.2003.03807.x
- Waldo, 2005, Identification and complementation of a mutation associated with loss of Mycoplasma pneumoniae virulence-specific proteins B and C, J Bacteriol, 187, 747, 10.1128/JB.187.2.747-751.2005 · doi:10.1128/jb.187.2.747-751.2005
- Atkinson, 2008, Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections, FEMS Microbiol Rev, 32, 956, 10.1111/j.1574-6976.2008.00129.x · DOI · Paper page
- Wang, 2012, Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired pneumonia, Cochrane Database Syst Rev, 10, CD009175
- Bradley, 2011, The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America, Clin Infect Dis, 53, e25, 10.1093/cid/cir531 · DOI · Paper page
- Harris, 2011, British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011, Thorax, 66, ii1
- Spuesens, 2013, Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study, PLoS Med, 10, e1001444, 10.1371/journal.pmed.1001444 · DOI · Paper page
- Atkinson, 2014, Mycoplasma pneumoniae infections in childhood, Pediatr Infect Dis J, 33, 92, 10.1097/INF.0000000000000171 · doi:10.1097/inf.0000000000000171
- Adefurin, 2011, Ciprofloxacin safety in paediatrics: a systematic review, Arch Dis Child, 96, 874, 10.1136/adc.2010.208843 · doi:10.1136/adc.2010.208843
- Bebear, 2011, Mycoplasma pneumoniae: susceptibility and resistance to antibiotics, Future Microbiol, 6, 423, 10.2217/fmb.11.18 · DOI · Paper page
- Mulholland, 2012, Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children, Cochrane Database Syst Rev, 12, CD004875
- Matsuda, 2013, Gene and cytokine profile analysis of macrolide-resistant Mycoplasma pneumoniae infection in Fukuoka, Japan, BMC Infect Dis, 13, 591, 10.1186/1471-2334-13-591 · doi:10.1186/1471-2334-13-591
- Kawai, 2013, Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients, Antimicrobial Agents Chemother, 57, 4046, 10.1128/AAC.00663-13 · DOI
- Qu, 2013, Specific multilocus variable-number tandem-repeat analysis genotypes of Mycoplasma pneumoniae are associated with diseases severity and macrolide susceptibility, PLoS One, 8, e82174, 10.1371/journal.pone.0082174 · DOI
- Ma, 2014, Characterization of macrolide resistance of Mycoplasma pneumoniae in children in Shenzhen China, Pediatr Pulmonol, 49, 695, 10.1002/ppul.22851 · DOI
- Zhao, 2013, Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012, Antimicrobial Agents Chemother, 57, 1521, 10.1128/AAC.02060-12 · DOI
- Wu, 2013, Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Taiwan, Pediatr Pulmonol, 48, 904, 10.1002/ppul.22706 · DOI
- Uh, 2013, Macrolide resistance of Mycoplasma pneumoniae and its detection rate by real-time PCR in primary and tertiary care hospitals, Ann Lab Med, 33, 410, 10.3343/alm.2013.33.6.410 · DOI
- Hong, 2013, Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000–2011, Emerg Infect Dis, 19, 1281, 10.3201/eid1908.121455 · doi:10.3201/eid1908.121455
- Eshaghi, 2013, Macrolide-resistant Mycoplasma pneumoniae in humans, Ontario, Canada, 2010–2011, Emerg Infect Dis, 19, 1525, 10.3201/eid1909.121466 · doi:10.3201/eid1909.121466
- Dumke, 2013, Low rate of macrolide resistance in Mycoplasma pneumoniae strains in Germany between 2009 and 2012, Antimicrobial Agents Chemother, 57, 3460, 10.1128/AAC.00706-13 · doi:10.1128/aac.00706-13
- Pereyre, 2013, The increased incidence of Mycoplasma pneumoniae in France in 2011 was polyclonal, mainly involving M. pneumoniae type 1 strains, Clin Microbiol Infect, 19, E212, 10.1111/1469-0691.12107 · doi:10.1111/1469-0691.12107
- Ferguson, 2013, Clinical outcomes and macrolide resistance in Mycoplasma pneumoniae infection in Scotland, UK, J Med Microbiol, 62, 1876, 10.1099/jmm.0.066191-0 · DOI
- Okazaki, 2001, Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro, Microbiol Immunol, 45, 617, 10.1111/j.1348-0421.2001.tb01293.x · DOI · Paper page
- Pereyre, 2004, In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae, Antimicrobial Agents Chemother, 48, 460, 10.1128/AAC.48.2.460-465.2004 · DOI
- Lucier, 1995, Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae, Antimicrobial Agents Chemother, 39, 2770, 10.1128/AAC.39.12.2770 · DOI · Paper page
- Averbuch, 2011, Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010, Emerg Infect Dis, 17, 1079, 10.3201/eid1706.101558 · doi:10.3201/eid1706.101558
- Hantz, 2012, Multilocus variable-number tandem-repeat analysis-confirmed emergence of a macrolide resistance-associated mutation in Mycoplasma pneumoniae during macrolide therapy for interstitial pneumonia in an immunocompromised child, J Clin Microbiol, 50, 3402, 10.1128/JCM.01248-12 · DOI
- Chironna, 2011, Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children, J Antimicrob Chemother, 66, 734, 10.1093/jac/dkr003 · DOI
- Liu, 2012, Multiclonal origin of macrolide-resistant Mycoplasma pneumoniae isolates as determined by multilocus variable-number tandem-repeat analysis, J Clin Microbiol, 50, 2793, 10.1128/JCM.00678-12 · DOI
- Morozumi, 2010, Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia, J Infect Chemother, 16, 78, 10.1007/s10156-009-0021-4 · DOI · Paper page
- Li, 2009, Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates, Pediatr Infect Dis J, 28, 693, 10.1097/INF.0b013e31819e3f7a · DOI
- Morozumi, 2008, Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia, Antimicrobial Agents Chemother, 52, 348, 10.1128/AAC.00779-07 · DOI · Paper page
- Suzuki, 2006, Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae, Antimicrobial Agents Chemother, 50, 709, 10.1128/AAC.50.2.709-712.2006 · DOI · Paper page
- Matsubara, 2009, A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients, J Infect Chemother, 15, 380, 10.1007/s10156-009-0715-7 · doi:10.1007/s10156-009-0715-7
- Kawai, 2013, Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients, Antimicrobial Agents Chemother, 57, 2252, 10.1128/AAC.00048-13 · doi:10.1128/aac.00048-13
- Okada, 2012, Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children, Clin Infect Dis, 55, 1642, 10.1093/cid/cis784 · DOI · Paper page
- Matsuoka, 2004, Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan, Antimicrobial Agents Chemother, 48, 4624, 10.1128/AAC.48.12.4624-4630.2004 · DOI · Paper page
- Labro, 1998, Anti-inflammatory activity of macrolides: a new therapeutic potential?, J Antimicrobial Chemother, 37, 10.1093/jac/41.suppl_2.37 · DOI · Paper page
Cited by
Mycoplasma pneumoniae from the Respiratory Tract and Beyond
Waites, K. B., Xiao, L., Liu, Y., Balish, M. F., & Atkinson, T. P. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00114-16 · Cited by 884
Mycoplasmas and Their Antibiotic Resistance: The Problems and Prospects in Controlling Infections
Chernova, O. A., Medvedeva, E. S., Mouzykantov, A. A., Baranova, N. B., & Chernov, V. M. (2016) · Acta Naturae · doi:10.32607/20758251-2016-8-2-24-34 · Cited by 66
Advances in adhesion-related pathogenesis in Mycoplasma pneumoniae infection
Sun, B., Ling, Y., Li, J., Ma, L., Jie, Z., Luo, H., Li, Y., Yin, G., Wang, M., Meng, F., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1613760 · Cited by 18
Metadata
- Authors
- Spuesens, E. B. M., Meyer Sauteur, P. M., Vink, C., & van Rossum, A. M. C.
- Venue
- Journal of Infection
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 69
- Pages
- S42-S46
- ISSN
- 0163-4453
- Cited by
- 47
- References
- 3
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- Swiss National Science Foundation (PBZHP3_147290)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.